Which of the following is NOT a characteristic of GP IIb/IIIa inhibitors?

GP IIb/IIIa inhibitors are a class of antiplatelet agents that play a significant role in managing acute coronary syndromes and are predominantly administered in clinical settings. The choice identifying that they are not oral medications is accurate because GP IIb/IIIa inhibitors are typically administered intravenously. This route of administration is essential for achieving rapid effects in acute settings, such as during percutaneous coronary interventions (like angioplasty), where immediate antiplatelet action is required.

The other characteristics highlight the clinical utility of GP IIb/IIIa inhibitors. They are indeed used for treating unstable angina and indicated for management during cardiac catheterization procedures, facilitating improved outcomes during these interventions. Furthermore, these inhibitors have been shown to be beneficial in the context of myocardial infarction treatment, where they help prevent thrombus formation and subsequent complications.

In summary, the intravenous administration route of GP IIb/IIIa inhibitors is pivotal for their effectiveness in acute coronary situations, distinguishing them from oral medications.